Mechanisms of troglitazone hepatotoxicity

Chemical Research in Toxicology

Volumn 16, Issue 6, 2003, Pages 679-687

  Smith, Martyn T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; BILE SALT; BOSENTAN; CARRIER PROTEIN; CYTOCHROME C; DRUG METABOLITE; GLIBENCLAMIDE; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; QUINONE DERIVATIVE; QUINONE METHIDE; RIFAMPICIN; ROSIGLITAZONE; TROGLITAZONE; TROGLITAZONE QUINONE; TROGLITAZONE SULFATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; BILE SALT EXPORT PUMP; BILIARY EXCRETION; CHOLESTASIS; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENZYME DEFICIENCY; ENZYME RELEASE; HEPATITIS; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER DYSFUNCTION; LIVER FAILURE; LIVER MITOCHONDRION; LIVER TOXICITY; METABOLIC ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREDICTION; REVIEW; STEATOSIS; TOXICITY TESTING;

ANIMALIA;

EID: 0038650658     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034033e     Document Type: Review

References (88)

1. Gale, E. A. (2001) Lessons from the glitazones: a story of drug development. Lancet 357, 1870-1875.
2. Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., and Bonkovsky, H. L. (2000) Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. J. Gastroenterol. 95, 272-276.
3. Bissell, D. M., Gores, G. J., Laskin, D. L., and Hoofnagle, J. H. (2001) Drug-induced liver injury: mechanisms and test systems. Hepatology 33, 1009-1013.
4. Loi, C. M., Young, M., Randinitis, E., Vassos, A., and Koup, J. R. (1999) Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 37, 91-104.
5. Kawai, K., Kawasaki-Tokui, Y., Odaka, T., Tsuruta, F., Kazui, M., Iwabuchi, H., Nakamura, T., Kinoshita, T., Ikeda, T., Yoshioka, T., Komai, T., and Nakamura, K. (1997) Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47, 356-368.
6. Preininger, K., Stingl, H., Englisch, R., Furnsinn, C., Graf, J., Waldhausl, W., and Roden, M. (1999) Acute troglitazone action in isolated perfused rat liver. Br. J. Pharmacol. 126, 372-378.
7. Haskins, J. R., Rowse, P., Rahbari, R., and de la Iglesia, F. A. (2001) Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol. 75, 425-438.
8. Kawai, K., Hirota, T., Muramatsu, S., Tsuruta, F., Ikeda, T., Kobashi, K., and Nakamura, K. I. (2000) Intestinal absorption and excretion of troglitazone sulphate, a major biliary metabolite of troglitazone. Xenobiotica 30, 707-715.
9. Honma, W., Shimada, M., Sasano, H., Ozawa, S., Miyata, M., Nagata, K., Ikeda, T., and Yamazoe, Y. (2002) Phenol Sulfotransferase, ST1A3, as the Main Enzyme Catalyzing Sulfation of Troglitazone in Human Liver. Drug Metab. Dispos. 30, 944-952.
10. Yoshigae, Y., Konno, K., Takasaki, W., and Ikeda, T. (2000) Characterization of UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in rats and humans. J. Toxicol. Sci. 25, 433-441.
11. Day, C. (1999) Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med. 16, 179-192.
12. Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., and Yokoi, T. (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260-1266.
13. Tettey, J. N., Maggs, J. L., Rapeport, W. G., Pirmohamed, M., and Park, B. K. (2001) Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14, 965-974.
14. Siegel, D., Bolton, E. M., Burr, J. A., Liebler, D. C., and Ross, D. (1997) The reduction of alpha-tocopherolquinone by human NAD-(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol. Pharmacol. 52, 300-305.
15. He, K., Woolf, T. F., Kindt, E. K., Fielder, A. E., and Talaat, R. E. (2001) Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. Biochem. Pharmacol. 62, 191-198.
16. Ramachandran, V., Kostrubsky, V. E., Komoroski, B. J., Zhang, S., Dorko, K., Esplen, J. E., Strom, S. C., and Venkataramanan, R. (1999) Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27, 1194-1199.
17. Sahi, J., Hamilton, G., Sinz, M., Barros, S., Huang, S. M., Lesko, L. J., and LeCluyse, E. L. (2000) Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30, 273-284.
18. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., and Baillie, T. A. (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14, 62-70.
19. Yamamoto, Y., Yamazaki, H., Ikeda, T., Watanabe, T., Iwabuchi, H., Nakajima, M., and Yokoi, T. (2002) Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 30, 155-160.
20. Smith, M. T., Redick, J. A., and Baron, J. (1983) Quantitative immunohistochemistry: a comparison of microdensitometric analysis of unlabeled antibody peroxidase-antiperoxidase staining and of microfluorometric analysis of indirect fluorescent antibody staining for nicotinamide adenosine dinucleotide phosphate (NAD-PH)-cytochrome c (P-450) reductase in rat liver. J. Histochem. Cytochem. 31, 1183-1189.
21. Smith, M. T., Loveridge, N., Wills, E. D., and Chayen, J. (1979) The distribution of glutathione in the rat liver lobule. Biochem. J. 182, 103-108.
22. Buhler, R., Lindros, K. O., Nordling, A., Johansson, I., and Ingelman-Sundberg, M. (1992) Zonation of cytochrome P450 isozyme expression and induction in rat liver. Eur. J. Biochem. 204, 407-412,
23. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135-160.
24. Thor, H., Smith, M. T., Hartzell, P., Bellomo, G., Jewell, S. A., and Orrenius, S. (1982) The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. J. Biol. Chem. 257, 12419-12425.
25. Schulz, W. A., Eickelmann, P., and Sies, H. (1996) Free radicals in toxicology: redox cycling and NAD(P)H: quinone oxidoreductase. Arch. Toxicol. Suppl. 18, 217-222.
26. McClain, C. J., Price, S., Barve, S., Devalarja, R., and Shedlofsky, S. (1999) Acetaminophen hepatotoxicity: An update. Curr. Gastroenterol. Rep. 1, 42-49.
27. Kostrubsky, V. E., Sinclair, J. F., Ramachandran, V., Venkataramanan, R., Wen, Y. H., Kindt, E., Galchev, V., Rose, K., Sinz, M., and Strom, S. C. (2000) The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab. Dispos. 28, 1192-1197.
28. Yoshioka, T., and Fujita, T. (1997) [Studies on compounds with antioxidant activity - development of hypoglycemic agents, troglitazone (CS-045)]. Yakugaku Zasshi 117, 597-610.
29. Narayanan, P. K., Hart, T., Elcock, F., Zhang, C., Hahn, L., McFarland, D., Schwartz, L., Morgan, D. G., and Bugelski, P. (2003) Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry 52A, 28-35.
30. Li, J., Kaneko, T., Wang, Y., Qin, L. Q., Wang, P. Y., and Sato, A. (2002) Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology 176, 91-100.
31. Hewitt, N. J., Lloyd, S., Hayden, M., Butler, R., Sakai, Y., Springer, R., Fackett, A., and Li, A. P. (2002) Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chem.-Biol. Interact. 142, 73-82.
32. Bae, M. A., Rhee, H., and Song, B. J. (2003) Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol. Lett. 139, 67-75.
33. Toyoda, M., Takagi, H., Horiguchi, N., Kakizaki, S., Sato, K., Takayama, H., and Mori, M. (2002) A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50, 563-567.
34. Boelsterli, U. A., and Bedoucha, M. (2002) Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem. Pharmacol. 63, 1-10.
35. Cheng-Lai, A., and Levine, A. (2000) Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis. 2, 326-333.
36. Greene, D. A. (1999) Rosiglitazone: a new therapy for Type 2 diabetes. Exp. Opin. Invest. Drugs 8, 1709-1719.
37. Marra, F., Efsen, E., Romanelli, R. G., Caligiuri, A., Pastacaldi, S., Batignani, G., Bonacchi, A., Caporale, R., Laffi, G., Pinzani, M., and Gentilini, P. (2000) Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119, 466-478.
38. Ott, P., Ranek, L., and Young, M. A. (1998) Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. Eur. J. Clin. Pharmacol. 54, 567-571.
39. Davies, G. F., Khandelwal, R. L., and Roesler, W. J. (1999) Troglitazone induces expression of PPARgamma in liver. Mol. Cell Biol. Res. Commun. 2, 202-208.
40. Berger, J., and Moller, D. E. (2002) The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435.
41. Hihi, A. K., Michalik, L., and Wahli, W. (2002) PPARs: transcriptional effectors of fatty acids and their derivatives. Cell. Mol. Life Sci. 59, 790-798.
42. Wyllie, A. H. (1997) Apoptosis: an overview. Br. Med. Bull. 53, 451-465.
43. Wyllie, A. H., and Golstein, P. (2001) More than one way to go. Proc. Natl. Acad. Sci. U.S.A. 98, 11-13.
44. Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., and Lemasters, J. J. (2002) Mechanisms of hepatotoxicity. Toxicol. Sci. 65, 166-176.
45. Jaeschke, H. (2002) Inflammation in response to hepatocellular apoptosis. Hepatology 35, 964-966.
46. Yamamoto, Y., Nakajima, M., Yamazaki, H., and Yokoi, T. (2001) Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci. 70, 471-482.
47. Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S., and Kawai, S. (2002) Nonsteroidal antiinflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J. Pharmacol. Exp. Ther. 302, 18-25.
48. Kim, Y., Suh, N., Sporn, M., and Reed, J. C. (2002) An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22320-22329.
49. Green, S. (1995) PPAR: a mediator of peroxisome proliferator action. Mutat. Res. 333, 101-109.
50. Lloyd, S., Hayden, M. J., Sakai, Y., Fackett, A., Silber, P. M., Hewitt, N. J., and Li, A. P. (2002) Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem.-Biol. Interact. 142, 57-71.
51. Bedoucha, M., Atzpodien, E., and Boelsterli, U. A. (2001) Diabetic KKAy mice exhibit increased hepatic PPARgammal gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol. 35, 17-23.
52. Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanan, P. K., Kurali, E., Hart, T. K., Thomas, H. C., and Schwartz, L. W. (2002) Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69, 131-138.
53. Tirmenstein, M., Hu, C., Gales, T., Maleeff, B., Narayanan, P., Kurali, E., Hart, T., Thomas, H., and Schwartz, L. (2003) Reply. Toxicol. Sci. 71, 282-284.
54. Ravagnan, L., Roumier, T., and Kroemer, G. (2002) Mitochondria, the killer organelles and their weapons. J. Cell. Physiol. 192, 131-137.
55. Smaili, S. S., Hsu, Y. T., Sanders, K. M., Russell, J. T., and Youle, R. J. (2001) Bax translocation to mitochondria after a rapid loss of mitochondrial membrane potential. Cell Death Differ. 8, 909-920.
56. Bae, M. A., and Song, B. J. (2003) Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol. Pharmacol. 63, 401-408.
57. Qian, T., Herman, B., and Lemasters, J. J. (1999) The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol. Appl. Pharmacol. 154, 117-125.
58. Lemasters, J. J. (1999) V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am. J. Physiol. 276, G1-G6.
59. Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627-635.
60. Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M., and Gasser, R. (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167, 83-98.
61. Kullak-Ublick, G. A., Beuers, U., and Paumgartner, G. (2000) Hepatobiliary transport. J. Hepatol. 32 (Suppl. 1), 3-18.
62. Patel, T., Steer, C. J., and Gores, G. J. (1999) Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis. Hepatology 30, 811-815.
63. Kwo, P., Patel, T., Bronk, S. F., and Gores, G. J. (1995) Nuclear serine protease activity contributes to bile acid-induced apoptosis in hepatocytes. Am. J. Physiol. 268, G613-G621.
64. Strautnieks, S. S., Bull, L. N., Knisely, A. S., Kocoshis, S. A., Dahl, N., Arnell, H., Sokal, E., Dahan, K., Childs, S., Ling, V., Tanner, M. S., Kagalwalla, A. F., Nemeth, A., Pawlowska, J., Baker, A., Mieli-Vergani, G., Freimer, N. B., Gardiner, R. M., and Thompson, R. J. (1998) A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20, 233-238.
65. Delzenne, N. M., Calderon, P. B., Taper, H. S., and Roberfroid, M. B. (1992) Comparative hepatotoxicity of cholic acid, deoxycholic acid and lithocholic acid in the rat: in vivo and in vitro studies. Toxicol. Lett. 61, 291-304.
66. Gores, G. J., Miyoshi, H., Botla, R., Aguilar, H. I., and Bronk, S. F. (1998) Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases. Biochim. Biophys. Acta 1366, 167-175.
67. Faubion, W. A., Guicciardi, M. E., Miyoshi, H., Bronk, S. F., Roberts, P. J., Svingen, P. A., Kaufmann, S. H., and Gores, G. J. (1999) Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103, 137-145.
68. Faubion, W. A., and Gores, G. J. (1999) Death receptors in liver biology and pathobiology. Hepatology 29, 1-4.
69. Miyoshi, H., Rust, C., Roberts, P. J., Burgart, L. J., and Gores, G. J. (1999) Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 117, 669-677.
70. Sodeman, T., Bronk, S. F., Roberts, P. J., Miyoshi, H., and Gores, G. J. (2000) Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G992-G999.
71. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., and Meier, P. J. (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231.
72. Shibuya, A., Watanabe, M., Fujita, Y., Saigenji, K., Kuwao, S., Takahashi, H., and Takeuchi, H. (1998) An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 21, 2140-2143.
73. Booth, A. M., Caldwell, S. H., and Iezzoni, J. C. (2000) Troglitazone-associated hepatic failure. Am. J. Gastroenterol. 95, 557-558.
74. Fukano, M., Amano, S., Sato, J., Yamamoto, K., Adachi, H., Okabe, H., Fujiyama, Y., and Bamba, T. (2000) Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum. Pathol. 31, 250-253.
75. Verbeeck, R. K., and Horsmans, Y. (1998) Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm. World Sci. 20, 183-192.
76. Morgan, D. J., and McLean, A. J. (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin. Pharmacokinet. 29, 370-391.
77. Fiatarone, J. R., Coverdale, S. A., Batey, R. G., and Farrell, G. C. (1991) Nonalcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. J. Gastroenterol. Hepatol. 6, 585-590.
78. Pessayre, D., Berson, A., Fromenty, B., and Mansouri, A. (2001) Mitochondria in steatohepatitis. Semin. Liver Dis. 21, 57-69.
79. Caldwell, S. H., Swerdlow, R. H., Khan, E. M., Iezzoni, J. C., Hespenheide, E. E., Parks, J. K., and Parker, W. D., Jr. (1999) Mitochondrial abnormalities in nonalcoholic steatohepatitis. J. Hepatol. 31, 430-434.
80. Shishido, S., Koga, H., Harada, M., Kumemura, H., Hanada, S., Taniguchi, E., Kumashiro, R., Ohira, H., Sato, Y., Namba, M., Ueno, T., and Sata, M. (2003) Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37, 136-147.
81. Caldwell, S. H., Hespenheide, E. E., and von Borstel, R. W. (2001) Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig. Dis. Sci. 46, 376-378.
82. Herman, J. R., Dethloff, L. A., McGuire, E. J., Parker, R. F., Walsh, K. M., Gough, A. W., Masuda, H., and De La Iglesia, F. A. (2002) Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol. Sci. 68, 226-236.
83. Rothwell, C., McGuire, E. J., Altrogge, D. M., Masuda, H., and de la Iglesia, F. A. (2002) Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J. Toxicol. Sci. 27, 35-47.
84. Graham, D. J., Drinkard, C. R., and Shatin, D. (2003) Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98, 175-179.
85. Ballet, F. (1997) Hepatotoxicity in drug development: detection, significance and solutions. J. Hepatol. 26 (Suppl. 2), 26-36.
86. Watkins, S. M., Reifsnyder, P. R., Pan, H. J., German, J. B., and Leiter, E. H. (2002) Lipid metabolome-wide effects of the PPAR-gamma agonist rosiglitazone. J. Lipid Res. 43, 1809-1817.
87. Shimabukuro, M., Zhou, Y. T., Lee, Y., and Unger, R. H. (1998) Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 273, 3547-3550.
88. Fujiwara, T., Okuno, A., Yoshioka, S., and Horikoshi, H. (1995) Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 44, 486-490.